Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $93

Benzinga Newsdesk www.benzinga.com Negative 57.9%

Neg 57.9% Neu 0% Pos 0%

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price target from $96 to $93.